Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
| العنوان: | Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation |
|---|---|
| المؤلفون: | Andrew E Sloan, Brian J. Williams, Veronica Chiang, Ganesh Rao, Peter E. Fecci, Steven Tatter, Kris A. Smith, Alireza M. Mohammadi, James E. Baumgartner, Kevin Judy, Zulma Tovar-Spinoza, Eric C. Leuthardt, Albert H. Kim, Sujit S. Prabhu, Constantinos G. Hadjipanayis, Clark C. Chen |
| المصدر: | Neurosurgery |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Quality of life, medicine.medical_specialty, Survival, Neuros/4, AcademicSubjects/MED00930, medicine.medical_treatment, Brain tumor, 03 medical and health sciences, 0302 clinical medicine, Robotic Surgical Procedures, Laser Interstitial Thermal Therapy, Neurosurgery 20/20: Concise, Clear Content, medicine, Humans, Prospective Studies, Registries, Karnofsky Performance Status, Adverse effect, Survival rate, ComputingMethodologies_COMPUTERGRAPHICS, Aged, Neuros/18, Brain Neoplasms, business.industry, Cancer, Middle Aged, medicine.disease, Ablation, Comorbidity, Laser ablation, Survival Rate, Treatment Outcome, Research—Human—Clinical Studies, LITT, 030220 oncology & carcinogenesis, Female, Surgery, Laser Therapy, Neurology (clinical), Radiology, business, 030217 neurology & neurosurgery |
| الوصف: | BACKGROUND Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature. Graphical Abstract Graphical Abstract |
| تدمد: | 1524-4040 0148-396X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746e5cd2f7e218578f84c5f4ab149de3Test https://doi.org/10.1093/neuros/nyaa071Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....746e5cd2f7e218578f84c5f4ab149de3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15244040 0148396X |
|---|